Can progression of valvular insufficiency (regurgitation) be slowed down?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, progression of valvular insufficiency can be slowed down through effective medical therapy and interventions. The most recent and highest quality study, 1, suggests that indications for intervention for valvular regurgitation are relief of symptoms and prevention of the irreversible long-term consequences of left ventricular volume overload. Key approaches to slowing down the progression of valvular regurgitation include:

  • Medical management focusing on controlling blood pressure, reducing cardiac workload, and managing symptoms
  • Use of ACE inhibitors, ARBs, beta-blockers, and diuretics to reduce afterload, decrease regurgitant volume, control heart rate, and relieve fluid overload symptoms
  • Lifestyle modifications such as maintaining optimal blood pressure, following a low-sodium diet, engaging in appropriate physical activity, achieving optimal weight, and avoiding tobacco
  • Regular echocardiographic monitoring to track disease progression These interventions work by reducing the pressure gradient across the affected valve, decreasing ventricular wall stress, preventing ventricular remodeling, and minimizing the hemodynamic burden on the heart, potentially slowing the progression of valvular regurgitation and delaying the need for surgical intervention, as supported by 1 and 1. In specific cases, such as severely symptomatic primary or secondary mitral regurgitation, mitral transcatheter edge-to-edge repair may be beneficial, as noted in 1. Additionally, surgical intervention may be considered for patients with severe symptomatic isolated tricuspid regurgitation or bioprosthetic valve dysfunction, as outlined in 1. Overall, a comprehensive approach combining medical management, lifestyle modifications, and timely interventions can help slow down the progression of valvular insufficiency and improve patient outcomes.

From the Research

Valvular Insufficiency Progression

The progression of valvular insufficiency, also known as regurgitation, can potentially be slowed down through various treatments.

  • Beta-blockers have been found to have a role in the management of valvular disorders, including the reduction of valve-related hemolysis and the prevention of atrial fibrillation 2.
  • Angiotensin converting enzyme (ACE) inhibitors have been shown to decrease preload and afterload, and may be of potential value in valvular regurgitation 3.
  • A study found that long-term ACE inhibition in patients with valvular regurgitation reverses left ventricular dilation and reduces left ventricular mass and hypertrophy, thereby improving left ventricular function 3.
  • Vasodilator drug therapy may also be beneficial for asymptomatic patients with severe aortic regurgitation and preserved left ventricular function 4.

Treatment Options

Different treatment options are available for valvular insufficiency, including:

  • Surgery, which is recommended for severe primary mitral regurgitation if persistent symptoms are present or if left ventricle dysfunction is present 5.
  • Coronary artery bypass grafts (CABG) or percutaneous coronary intervention (PCI) for severe mitral regurgitation due to ischemia 5.
  • Therapy of heart failure with vasodilators and diuretics to improve forward cardiac output in patients with secondary mitral regurgitation 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Beta-blocker therapy for valvular disorders.

The Journal of heart valve disease, 2011

Research

Hemodynamic and morphologic changes after long-term angiotensin converting enzyme inhibition in patients with chronic valvular regurgitation.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1994

Research

Aortic regurgitation: disease progression and management.

Nature clinical practice. Cardiovascular medicine, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.